Small caps round-up: Byotrol, sareum, KDD ...
19th Jul 2012 12:07
Byotrol, an anti-microbial hygiene company, has continued to make progress and has maintained the momentum seen in the second half of last year into the current financial year. The balance sheet continues to remain strong and is well positioned to its objective of positive cash generation at the ear
Read moreSmall caps round-up: Cyan, Aer Lingus, Mobile Tornado ...
7th Jun 2012 13:59
Cyan Holdings, the wireless solutions company, has revealed that three more Cyan partners have received requests from the Tamil Nadu Electricity Board (TNEB) Automatic Meter Reading tender to proceed with installation and commissioning of 500 unit pilots within the next 25 days. The news follows Cya
Read moreSmall caps round-up: PLUS Markets, Sareum, Planet Payment
6th Jun 2012 14:22
PLUS Markets Group, which provides listing and quoting services to around 140 companies on the stock exchange, has recommended its shareholders to vote in favour of the proposed disposal of its PLUS-SX division to ICAP for a nominal sum at its general meeting on June 18th. 'The disposal will, theref
Read moreSareum confident of at least one deal in 2012
27th Feb 2012 14:57
Penny stock Sareum, which develops drugs to combat cancer, saw its losses widen in the second half of 2011, in line with the board's expectations. The firm's losses after tax deepened from £0.26m to £0.33m, which the firm said reflects an increase in research and development. Pre-tax losses totall
Read moreCancer results boost Sareum
15th Aug 2011 11:50
Cancer drug discovery business Sareum shot ahead after it said it had selected a "preclinical development candidate" from research into Chk1, a method of controlling a cancer cells' response to DNA damage. The candidate, when orally dosed, reduces cancer growth rates compared to treatment with the
Read moreSareum soars after colon cancer study
4th Mar 2011 11:08
Shares in Sareum were soaring after the cancer drug discovery business announced positive results from a study into colon cancer. The study, which was conducted by the Institute of Cancer Research, founded that Sareum's Chk1 inhibitor, used alongside a gemcitabine, a chemotherapeutic, "demonstrate
Read moreSareum narrows losses
21st Feb 2011 15:56
Sareum, the cancer drug discovery business that earlier this month shot up after announcing positive results from a leukaemia study, narrowed losses in the half year to 31 December. Pre-tax losses narrowed to £281,000 from £321,000 over the same period a year ago. "Recent fundraisings provide us w
Read moreSmall caps round-up: Henry Boot, Firestone Diamonds, Amino Tech...
7th Feb 2011 11:52
Property developer Henry Boot says it will move to a net cash position after it agreed the sale of a shopping centre in Ayr for £33.8m and the sale of land with planning permission to build houses in Buckingham for an undisclosed fee. Henry Boot said last month that one of its goals is to 'manage d
Read moreSmall caps round-up: Amphion, Bioquell, Ablon...
16th Mar 2010 10:50
Shares in Amphion Innovations jumped after the medical and technology sector said it was cautious but confident in the strength of its model following a year which saw revenue increase to $8.6m from $7.1m in 2008, but losses increase to $2.9m from $1.8m. Shares in Bioquell moved in the other direct
Read moreSmall caps round-up: ING Real, Intellego, Oxford Intruments...
20th Jan 2010 13:10
ING UK Real Estate Income Trust will repay £15m of debt through the purchase and cancellation of loan notes at a discount to nominal value in two separate transactions. The transaction will result in a one off gain to NAV expected to be in the order of £680,000, and will also save over £719,000 per
Read moreSmall caps round-up: Ariana, Gemfields, Sareum
27th Oct 2009 11:09
Turkey-focused gold miner Ariana Resources has set up a 50:50 joint venture to combine its two main projects, Sindirgi and Tavsan, into a single conceptual entity. The company confirmed its partner in the 'Red Rabbit' project as Turkish turn-key construction firm Proccea Construction. "A Memorandu
Read moreSmall caps round-up: ProStrakan, Sareum,Sirius
6th Oct 2009 09:47
Speciality pharmaceutical company ProStrakan's New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA). Subject to successful completion of the US approval process, the Scottish firm plans to launch Abstral, which helps ease pain for
Read more